收费全文 | 38278篇 |
免费 | 2564篇 |
国内免费 | 206篇 |
耳鼻咽喉 | 365篇 |
儿科学 | 691篇 |
妇产科学 | 525篇 |
基础医学 | 5338篇 |
口腔科学 | 991篇 |
临床医学 | 3830篇 |
内科学 | 8140篇 |
皮肤病学 | 722篇 |
神经病学 | 4376篇 |
特种医学 | 2093篇 |
外科学 | 5917篇 |
综合类 | 243篇 |
一般理论 | 7篇 |
预防医学 | 1907篇 |
眼科学 | 846篇 |
药学 | 2290篇 |
中国医学 | 75篇 |
肿瘤学 | 2692篇 |
2023年 | 260篇 |
2022年 | 454篇 |
2021年 | 952篇 |
2020年 | 687篇 |
2019年 | 888篇 |
2018年 | 1014篇 |
2017年 | 860篇 |
2016年 | 1003篇 |
2015年 | 1221篇 |
2014年 | 1464篇 |
2013年 | 1813篇 |
2012年 | 2911篇 |
2011年 | 2994篇 |
2010年 | 1791篇 |
2009年 | 1603篇 |
2008年 | 2607篇 |
2007年 | 2596篇 |
2006年 | 2465篇 |
2005年 | 2406篇 |
2004年 | 2173篇 |
2003年 | 1988篇 |
2002年 | 1828篇 |
2001年 | 467篇 |
2000年 | 370篇 |
1999年 | 401篇 |
1998年 | 377篇 |
1997年 | 282篇 |
1996年 | 230篇 |
1995年 | 208篇 |
1994年 | 188篇 |
1993年 | 176篇 |
1992年 | 187篇 |
1991年 | 153篇 |
1990年 | 146篇 |
1989年 | 139篇 |
1988年 | 115篇 |
1987年 | 118篇 |
1986年 | 125篇 |
1985年 | 105篇 |
1984年 | 100篇 |
1983年 | 95篇 |
1982年 | 85篇 |
1981年 | 73篇 |
1980年 | 50篇 |
1979年 | 77篇 |
1978年 | 58篇 |
1977年 | 53篇 |
1976年 | 60篇 |
1974年 | 58篇 |
1973年 | 46篇 |
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献Forensic age estimation generally involves considerable amounts of uncertainty. Forensic age indicators such as teeth or skeleton images predict age only approximately, and this is likely to remain true even for future forensic age indicators. Thus, forensic age assessment should aim to make the best possible decisions under uncertainty. In this paper, we apply mathematical theory to make statistically optimal decisions to age assessment. Such an application is fairly straightforward assuming there is a standardized procedure for obtaining age indicator information from individuals, assuming we have data from the application of this procedure to a group of persons with known ages, and assuming the starting point for each individual is a probability distribution describing prior knowledge about the persons age. The main problem is then to obtain such a prior. Our analysis indicates that individual priors rather than a common prior for all persons may be necessary. We suggest that caseworkers, based on individual case information, may select a prior from a menu of priors. We show how information may then be collected over time to gradually increase the robustness of the decision procedure. We also show how replacing individual prior distributions for age with individual prior odds for being above an age limit cannot be recommended as a general method. Our theoretical framework is applied to data where the maturity of the distal femur and the third molar is observed using MRI. As part of this analysis we observe a weak positive conditional correlation between maturity of the two body parts.
相似文献